ArticleBreast (Edinburgh, Scotland)2023

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.

Binliang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.